Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Leerink on Spyre (SYRE): 'one of our Top Picks for 2026'
April 13, 2026 8:21 AM EDTLeerink Partners analyst Thomas J. Smith reiterated an Outperform rating on Spyre (NASDAQ: SYRE).
The analyst comments "SYRE (OP) announced positive topline results from the open-label SPY001 (anti-47) monotherapy cohort of the Phase 2 SKYLINE platform trial in ulcerative colitis (UC). Importantly, SPY001 demonstrated class-leading efficacy on the study's primary and key secondary endpoints, showing an impressive -9.2pt reduction from baseline on the primary RHI endpoint and a 40% clinical remission rate at week 12 - both data points suggesting differentiated efficacy relative to TAK's (NR)... More
Guggenheim on Top Pick Spyre (SYRE): 'We expect the stock could be up >40% on today's news'
April 13, 2026 7:46 AM EDTGuggenheim analyst Yatin Suneja reiterated a Buy rating and $115.00 price target on Spyre (NASDAQ: SYRE).
The analyst comments "Spyre announced topline results for SPY001's monotherapy study in SKYLINE-UC Part A (n~130). Across multiple endpoints (RHI from baseline, clinical remission, endoscopic improvement), SPY001/47 consistently outperformed TAK's Entyvio (both Week 6 & 14 comps), with most notable efficacy outcome of 40% clinical remission at week 12 (Fig 1 & 2). The induction CR data is one of the highest we have seen and significantly... More
